Cargando…
Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2
Severe acute respiratory syndrome coronovirus-2 (SARS-CoV-2) is the cause of the coronavirus disease 2019 (COVID-19) pandemic. Vaccination is considered the core approach to containing the pandemic. There is currently insufficient evidence on the efficacy of these vaccines in immunosuppressed inflam...
Autores principales: | Vollenberg, Richard, Tepasse, Phil-Robin, Kühn, Joachim Ewald, Hennies, Marc, Strauss, Markus, Rennebaum, Florian, Schomacher, Tina, Boeckel, Göran, Lorentzen, Eva, Bokemeyer, Arne, Nowacki, Tobias Max |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774019/ https://www.ncbi.nlm.nih.gov/pubmed/35052849 http://dx.doi.org/10.3390/biomedicines10010171 |
Ejemplares similares
-
Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study
por: Vollenberg, Richard, et al.
Publicado: (2022) -
Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022) -
Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022) -
Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
por: Dickerman, Barbra A., et al.
Publicado: (2021) -
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
por: Thompson, Mark G., et al.
Publicado: (2021)